Single Blog

What Are PROTACs and Why Do They Matter in Cancer Therapy?

Proteolysis-Targeting Chimeras (PROTACs) are a disruptive class of small molecule drugs designed not just to block a protein, but to eliminate it from the cell. Instead of occupying an active site like traditional inhibitors, PROTACs hijack the cell’s ubiquitin–proteasome system and mark disease-driving proteins for destruction.

A typical PROTAC consists of three modular components:

• Target ligand – binds the protein of interest (e.g., an oncogenic receptor)
• E3 ligase ligand – recruits an E3 ubiquitin ligase
• Linker – a chemical spacer that brings both proteins into proximity

Once the ternary complex forms, the target protein is ubiquitinated and sent to the proteasome for degradation. Because this is an event-driven process, a single PROTAC molecule can degrade multiple protein copies, offering a catalytic advantage over classical occupancy-based inhibitors doi:10.1038/nrd.2017.152.

Why Small Molecule PROTACs Are a Game Changer in Oncology

Cancer cells rely on aberrant proteins—mutant kinases, transcription factors, fusion oncoproteins—that often lack druggable pockets. PROTACs bypass this limitation by converting these “undruggable” targets into degradable substrates.

Key Advantages for Cancer Treatment

• Access to undruggable space: Transcription factors, scaffolding proteins, and nuclear receptors can be selectively degraded rather than imperfectly inhibited.
• Overcoming resistance: When tumors acquire mutations that reduce inhibitor binding, complete protein removal can circumvent certain resistance pathways.
• Deep and sustained target knockdown: Continuous degradation can yield more durable pathway suppression than transient occupancy.
• Potentially lower doses: Catalytic action means less compound may be needed to achieve therapeutic effects, with possible safety benefits.

Preclinical data show that PROTACs targeting oncogenic drivers such as BCR-ABL, BTK, and mutant EGFR can induce robust tumor cell death where traditional inhibitors fall short doi:10.1016/j.cell.2019.11.031.

Clinical Trailblazers: ARV-110 and ARV-471 in Hormone-Driven Cancers

ARV-110 (Bavdegalutamide) for Prostate Cancer

ARV-110 is an orally bioavailable PROTAC designed to degrade the androgen receptor (AR), a central driver of metastatic castration-resistant prostate cancer (mCRPC). Unlike conventional anti-androgens that simply block AR signaling, ARV-110 removes both wild-type and mutant AR variants from the cell.

Early clinical studies have reported PSA declines and radiographic responses in heavily pretreated mCRPC patients, including those with AR mutations associated with resistance to enzalutamide and abiraterone doi:10.1158/2159-8290.CD-20-1624.

ARV-471 (Vepdegestrant) for ER-Positive Breast Cancer

ARV-471 targets the estrogen receptor (ER) in ER-positive, HER2-negative breast cancer. While selective estrogen receptor degraders (SERDs) already exist, ARV-471 leverages the PROTAC mechanism to achieve more profound and sustained ER degradation.

Phase I/II data suggest meaningful tumor shrinkage and disease control in patients with endocrine-resistant disease, pointing to a potential new standard for advanced ER-positive breast cancer doi:10.1158/1538-7445.SABCS21-P5-04-02.

Design Challenges: What Stands Between PROTACs and Widespread Use?

Despite their promise, PROTACs are not plug-and-play. Medicinal chemists face several hurdles on the path from concept to clinic:

• Drug-like properties: PROTACs are larger and more polar than classical small molecules, complicating oral absorption, cell permeability, and tissue distribution.
• Selectivity and safety: Misrecruitment of off-target proteins to the E3 ligase can trigger unintended degradation and toxicity.
• E3 ligase diversity: Most clinical candidates use CRBN or VHL. Expanding the E3 ligase toolbox is essential for tissue-specific and tumor-selective degradation.

Structure-based design, linker engineering, and high-throughput ternary complex modeling are rapidly improving PROTAC developability and pharmacokinetics doi:10.1021/acs.jmedchem.0c00683.

The Next Frontier: AI-Driven, Patient-Tailored PROTACs

The convergence of AI and targeted protein degradation is poised to redefine precision oncology. By integrating structural biology, proteomics, and real-world response data, AI models can:

• Predict optimal linker length, rigidity, and exit vectors for stable ternary complex formation
• Rank E3 ligase options for tumor-selective degradation profiles
• Prioritize PROTAC candidates with favorable ADME, safety, and resistance-avoidance signatures

In the future, genomic profiling of an individual tumor could be directly linked to an AI-powered design pipeline that outputs bespoke PROTACs targeting that patient’s unique driver proteins. This vision—small molecule degraders, rationally engineered and algorithmically optimized—signals a powerful shift from “blocking” cancer to erasing its molecular engines.

References

• Pettersson M, Crews CM. PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future. Nat Rev Drug Discov. 2019;18(6):421–446. doi:10.1038/nrd.2017.152
• Burslem GM, Crews CM. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery. Cell. 2020;181(1):102–114. doi:10.1016/j.cell.2019.11.031
• Neklesa TK et al. ARV-110: An Androgen Receptor PROTAC Degrader for Prostate Cancer. Cancer Discov. 2021;11(11):2680–2695. doi:10.1158/2159-8290.CD-20-1624
• Flanagan JJ et al. ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer. Cancer Res. 2022;82(4 Suppl):P5-04-02. doi:10.1158/1538-7445.SABCS21-P5-04-02
• Testa A et al. PROTACs: A New Frontier in Drug Discovery. J Med Chem. 2020;63(16):8667–8692. doi:10.1021/acs.jmedchem.0c00683